NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Natus Medical Inc. (“Natus” or the “Company”) (NASDAQ:BABY).
The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose the risk of unfulfilled payments from its contract with Venezuela’s Ministry of Health leading to a material decline in the Company’s revenues and profitability.
Specifically, on April 4, 2016, the Company announced lower-than-expected preliminary 2016 first quarter revenue of about $87.5 million, lower than its previous guidance of $91.5 million to $92.5 million, and below analysts’ expectations. The Company cited the previously unexpected cancellation of key government supply contracts as a reason for the disappointing results.
Request more information now by clicking here: www.faruqilaw.com/BABY. There is no cost or obligation to you.
If you invested in Natus stock or options and would like to discuss your legal rights, visit www.faruqilaw.com/BABY. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to email@example.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Natus’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.